Pharmacological treatment for prevention of restenosis

Bibliography

• www.americanheart.org American Heart Association's 2000 Heart and Stroke Statistical Update.
   Google Scholar
• MEHRAN R, DANGAS G, ABIZAID AS et al.: Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation (1999) 100(18):1872–1878.
   PubMed Web of Science ®Google Scholar
• BARI INVESTIGATORS: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularisation Investigation (BARI). N Engl. J. Med. (1996) 335(4):217–225.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, UNGER F, SOUSA JE et al.: Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl. J. Med. (2001) 344(15):1117–1124.
   PubMed Web of Science ®Google Scholar
• ABIZAID A, KORNOWSKI R, MINTZ GS et al.: The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J. Am. Coll. Cardiol. (1998) 32(3):584–589.
   Google Scholar
• ELEZI S, KASTRATI A, PACHE J et al.: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J. Am. Coll. Cardiol. (1998) 32(7):1866–1873.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, DIRSCHINGER J, SCHOMIG A: Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. (2000) 25(1):34–46.
   PubMed Web of Science ®Google Scholar
• RIBICHINI F, STEFFENINO G, DELLAVALLE A et al.: Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation (1998) 97(2):147–154.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, SCHOMIG A, SEYFARTH M et al.: PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation (1999) 99(8):1005–1010.
   PubMed Web of Science ®Google Scholar
• STRAUSS BH, LAU HK, BOWMAN KA et al.: Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation (1999) 100(15):1616–1622.
   PubMed Web of Science ®Google Scholar
• MITTAL S, WEISS DL, HIRSHFELD JW, KOLANSKY DM, HERRMANN HC: Comparison of outcome after stenting for de novo versus restenotic narrowings in native coronary arteries. Am. J. Cardiol. (1997) 80(6):711–715.
   PubMed Web of Science ®Google Scholar
• ELEZI S, KASTRATI A, NEUMANN FJ et al.: Vessel size and long-term outcome after coronary stent placement. Circulation (1998) 98(18):1875–1880.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, ELEZI S, DIRSCHINGER J et al.: Influence of lesion length on restenosis after coronary stent placement. Am. J. Cardiol. (1999) 83(12):1617–1622.
   PubMed Web of Science ®Google Scholar
• ELEZI S, KASTRATI A, WEHINGER A et al.: Clinical and angiographic outcome after stent placement for chronic coronary occlusion. Am. J. Cardiol. (1998) 82(6):803–806, A9.
   PubMed Web of Science ®Google Scholar
• DE FEYTER PJ, VAN SUYLEN RJ, DE JAEGERE PP, TOPOL EJ, SERRUYS PW: Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J. Am. Coll. Cardiol. (1993) 21(7):1539–549.
   PubMed Web of Science ®Google Scholar
• WEBB JG, MYLER RK, SHAW RE et al.: Coronary angioplasty after coronary bypass surgery: initial results and late outcome in 422 patients. J. Am. Goa Cardiol. (1990) 16(4):812–820.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, SCHOMIG A, ELEZI S et al.: Predictive factors of restenosis after coronary stent placement. J. Am. Coll. Cardiol. (1997) 30(6):1428–1436.
   Google Scholar
• FOLEY DP, MELKERT R, SERRUYS PW: Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation (1994) 90(3):1239–1251.
   PubMed Web of Science ®Google Scholar
• FITZGERALD PJ, OSHIMA A, HAYASE M et al.: Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation (2000) 102(5):523–530.
   PubMed Web of Science ®Google Scholar
• MINTZ GS, POPMA JJ, PICHARD AD. et al.: Arterial remodelling after coronary angioplasty: a serial intravascular ultrasound study. Circulation (1996) 94(1):35–43.
   PubMed Web of Science ®Google Scholar
• DI MARIO C, GIL R, CAMENZIND E et al.: Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am. j Cardiol. (1995) 75(12):772–777.
   Google Scholar
• MINTZ GS: Remodelling and restenosis:observations from Serial Intravascular Ultrasound Studies. Curr. Interventional Cardiol. Reports (2000) 2(4):316–325.
   PubMedGoogle Scholar
• SERRUYS PW, VAN HOUT B, BONNIER H et al.: Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet (1998) 352(9129):673–681.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl. j Med. (1994) 331(8):489–495.
   PubMed Web of Science ®Google Scholar
• BETRIU A, MASOTTI M, SERRA A et al.: Randomised comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. j Am. Coll. Cardiol. (1999) 34(5):1498–1506.
   Google Scholar
• COHEN DJ, KRUMHOLZ HM, SUKIN CA et al.: In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomised clinical trial. Stent Restenosis Study Investigators. Circulation (1995) 92(9):2480–2487.
   PubMed Web of Science ®Google Scholar
• SAVAGE MP, DOUGLAS JS, FISCHMAN DL et al.: Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl. J. Med. (1997) 337(11):740–747.
   PubMed Web of Science ®Google Scholar
• ERBEL R, HAUDE M, HOPP HW et al.: Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl. j Med. (1998) 339(23):1672–1678.
   PubMed Web of Science ®Google Scholar
• ROGERS C, WELT FG, KARNOVSKY MJ, EDELMAN ER: Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vase. Biol. (1996) 16(10):1312–1318.
   PubMed Web of Science ®Google Scholar
• ALBIERO R, COLOMBO A: European high-activity (32)P radioactive stent experience. j Invasive Cordial. (2000)12(8):416–421.
   PubMed Web of Science ®Google Scholar
• ALBIERO R, NISHIDA T, ADAMIAN M et al.: Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation (2000) 101(21):2454–2457.
   PubMed Web of Science ®Google Scholar
• KUNTZ RE, SAFIAN RD, CARROZZA JP et al.: The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation (1992) 86(6):1827–1835.
   PubMed Web of Science ®Google Scholar
• CANTOR WJ, HELLKAMP AS, PETERSON ED et al.: Achieving optimal results with standard balloon angioplasty. J. Am. Goa Cardiol. (2001) (In Press).
   PubMedGoogle Scholar
• ISHIWATA S, ROBINSON K, CHRONOS N, CROCKER IR, KING SB III: Irradiation and postangioplasty restenosis: a recent overview. Jpn Heart J. (2000) 41(5):541–570.
   PubMedGoogle Scholar
• MINTZ GS, WEISSMAN NJ, TEIRSTEIN PS et al.: Effect of intracoronary gamma-radiation therapy on in-stent restenosis: an intravascular ultrasound analysis from the gamma-1 study. Circulation (2000) 102(24):2915–2918.
   PubMed Web of Science ®Google Scholar
• KUNTZ RE, BAIM DS: Prevention of coronary restenosis: the evolving evidence base for radiation therapy. Circulation (2000) 101(18):2130–2133.
   PubMed Web of Science ®Google Scholar
• WAKSMAN R, BHARGAVA B, WHITE L et al.: Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation (2000) 101(16):1895–1898.
   PubMed Web of Science ®Google Scholar
• WAKSMAN R: Vascular brachytherapy: update on clinical trials. J. Invasive Cardiol. (2000) 12(Suppl. A):18A–28A.
   Google Scholar
• TEIRSTEIN PS, MASSULLO V, JANI S et al.: Three-year clinical and angiographic follow-up after intracoronary radiation :results of a randomised clinical trial. Circulation (2000) 101(4):360–365.
   PubMed Web of Science ®Google Scholar
• KING SB III: Radiation for restenosis: watchful waiting. Circulation (1999) 99(2):192–194.
   PubMed Web of Science ®Google Scholar
• RAIZNER AE, OESTERLE SN, WAKSMAN R et al.: Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation (2000) 102(9):951–958.
   PubMed Web of Science ®Google Scholar
• FARB A, SHROFF S, JOHN M, SWEET W, VIRMANI R: Late arterial responses (6 and 12 months) after (32)P beta-emitting stent placement: sustained intimal suppression with incomplete healing.Circulation (2001) 103(14):1912–1919.
   PubMed Web of Science ®Google Scholar
• ALBIERO R, ADAMIAN M, KOBAYASHI N et al.: Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study. Circulation (2000) 101(1):18–26.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, KAY IP: I like the candy, I hate the wrapper: the (32)P radioactive stent. Circulation (2000) 101(1):3–7.
   PubMed Web of Science ®Google Scholar
• Clinica 917. PJB Publications (17/07/00).
   Google Scholar
• REICIN G, LIOTTA MC: Guide to Interventional Cardiology - Update 2000. Equity Research North America (2000):17.
   Google Scholar
• HOFFMANN R, MINTZ GS: Coronary in-stent restenosis - predictors, treatment and prevention. Eur. Heart j (2000) 21(20:1739–1749.
   PubMedGoogle Scholar
• BULT H: Restenosis: a challenge for pharmacology. Trends Pharmacol. Sci. (2000) 21(7):274–279.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR B, TANGUAY JF: Platelets and restenosis. J Am. Goa Cardiol. (2000) 35(3):555–562.
   PubMed Web of Science ®Google Scholar
• ROSANIO S, TOCCHI M, PATTERSON C, RUNGE MS: Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb. Haemost. (1999) 82(Suppl. 1) :164–170.
   PubMedGoogle Scholar
• CASTERELLA PJ, TEIRSTEIN PS: Prevention of coronary restenosis. Cardiol. Rev. (1999) 7(4):219–231.
   PubMedGoogle Scholar
• HAMON M, LECLUSE E, MONASSIER JP, GROLLIER G, POTIER JC: Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging (1998) 13(4):291–301.
   Google Scholar
• WURDEMAN RL, HILLEMAN DE, MOOSS AN: Restenosis, the Achilles' heel of coronary angioplasty. Pharmacotherapy (1998) 18(5):1024–1040.
   PubMed Web of Science ®Google Scholar
• FELDMAN LJ, RIESSEN R, STEG PG: Prevention of restenosis after coronary angioplasty: towards a molecular approach? Fundam. Clin. Pharmacol. (1995) 9(1):8–16.
   PubMed Web of Science ®Google Scholar
• HERRMAN JP, HERMANS WR, VOS J, SERRUYS PW: Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part I).Drugs (1993) 46(1):18–
   Google Scholar
• HERRMAN JP, HERMANS WR, VOS J, SERRUYS PW: Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II). Drugs (1993) 46(2):249–262.
   PubMed Web of Science ®Google Scholar
• MACH F: Toward new therapeutic strategies against neointimal formation in restenosis. Arterioscler. Thromb. Vase. Biol. (2000) 20(7): 1699–1700.
   PubMed Web of Science ®Google Scholar
• LANDZBERG BR, FRISHMAN WH, LERRICK K: Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog. Cardiovasc. Dis. (1997) 39(4):361–398.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, TOPOL EJ: Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog. Cardiovasc. Dis. (1997) 40(2):141–158.
   PubMed Web of Science ®Google Scholar
• DE FEYTER PJ, VOS J, RENSING BJ: Anti-restenosis trials. Curr. Interventional CardioL Rep. (2000) 2(0326–331.
   PubMedGoogle Scholar
• GRUBERG L, WAKSMAN R, SATLER LF, PICHARD AD, KENT KM: Novel approaches for the prevention of restenosis. Expert Opin. Investig. Drugs. (2000) 9(11):2555–2578.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, CALIFF RM, TOPOL EJ: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. j Am. coa CardioL (2000) 35(5):1103–1115.
   PubMed Web of Science ®Google Scholar
• CHAN AW, CHEW DP, LINCOFF AM: Update on Pharmacology for Restenosis. Curr. Interv. CardioL Rep. (2001) 3(2):149–155.
   PubMedGoogle Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF et al.: Randomised trial of coronary intervention with antibody against platelet integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet (1994) 343(8902):881–886.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, CALIFF RM, MOLITERNO DJ et al.: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/ IIIa receptors. Evaluation of Platelet IIb/Illa Inhibition in Stenting Investigators. N. EngL j Med. (1999) 341(5):319–327.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-lib/Ilia blockade. Evaluation of Platelet IIb/Illa Inhibitor for Stenting. Lancet (1998) 352(9122):87–92.
   Google Scholar
• MUKHERJEE D, REGINELLI JP, MOLITERNO DJ et al.: Unexpected Mortality Reduction with Abciximab for In-Stent Restenosis. J. Invasive CardioL (2000) 12(1 1 ):540–544.
   PubMedGoogle Scholar
• LINCOFF AM: Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularisation in patients with diabetes mellitus: results of the EPISTENT trial. Am. Heart j (2000) 139(2 Pt 2):546–52.
   Google Scholar
• BLINDT R, BOSSERHOFF AK, ZEIFFER U et al.: Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells. J. MoL Cell. CardioL (2000) 32(12):2195–2206.
   PubMed Web of Science ®Google Scholar
• BARON JH, MOISEEVA EP, DE BONO DP, ABRAMS KR, GERSHLICK AH: Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 fab (abciximab): a possible mechanism for influencing restenosis. Cardiovasc. Res. (2000) 48(3):464–472.
   PubMed Web of Science ®Google Scholar
• GIBSON CM, GOEL M, COHEN DJ et al.: Six-month angiographic and clinical follow-up of patients prospectively randomised to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomised Efficacy Study of Tirofiban for Outcomes and Restenosis. J. Am. Coll. CardioL (1998) 32(1 ):2 8–34.
   PubMed Web of Science ®Google Scholar
• O'SHEA JC, TCHENG JE: Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results. Curr. Interv. CardioL Rep. (2001) 3(1):62–68.
   PubMedGoogle Scholar
• ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356(9247):2037–2044.
   PubMed Web of Science ®Google Scholar
• THE ERASER INVESTIGATORS: Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation (1999) 100(8):799–806.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, KASTRATI A, SCHMITT C et al.: Effect of glycoprotein lib/Ilia receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. CardioL (2000) 35(4):915–921.
   PubMed Web of Science ®Google Scholar
• SIMON DI, DHEN Z, SEIFERT P et al.: Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J. Clin. Invest. (2000) 105(3):293–300.
   PubMed Web of Science ®Google Scholar
• CHICO TJ, CHAMBERLAIN J, GUNN J et al.: Effect of selective or combined inhibition of integrins alpha(llb)beta(3) and alpha(v)beta(3) on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation (2001) 103(8):1135–1141.
   PubMed Web of Science ®Google Scholar
• CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein lib/Ilia antagonists: a meta-analysis of phase III multicenter randomised trials. Circulation (2001) 103(2):201–206.
   PubMed Web of Science ®Google Scholar
• HAYASHI S, MORISHITA R, MATSUSHITA H et al.: Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21 Hypertension (2000) 35(1 Pt 2):237–243.
   Google Scholar
• ISHIZAKA N, TAGUCHI J, KIMURA Y et al.: Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis (1999) 142(1):41–46.
   PubMed Web of Science ®Google Scholar
• TSUCHIKANE E, FUKUHARA A, KOBAYASHI T et al.: Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation (1999) 100(1):21–26.
   PubMed Web of Science ®Google Scholar
• TAKES, MATSUTANI M, UEDA H et al: Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. J. CardioL (1997) 79(8):1097–1099.
   PubMed Web of Science ®Google Scholar
• TSUCHIKANE E, KATOH O, SUMITSUJI S et al.: Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am. Heart j (1998) 135(3):495–502.
   PubMed Web of Science ®Google Scholar
• KUNISHIMA T, MUSHA H, ETO F et al.: A randomised trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin. Ther. (1997) 19(5):1058–1066.
   PubMed Web of Science ®Google Scholar
• MIZOGUCH K, INOUE T, KAMISHIRADO H et al.: A randomised comparison of cilostazol vs. ticlopidine after coronary stent implantation [abstract]. Circulation (2000) 102(Suppl. II):730 (Abstract 3532).
   Google Scholar
• KOZUMA K, HARA K, YAMASAKI M et al.: Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am. Heart j (2001) 141(1):124–130.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, TSUMURA Y, YOSHIDA A et al.: Impact of Cilostazol on restenosis after AVE-GFX stent implantation. Am. J.Cardiol. (2000) 86(Suppl. 8A):120i (Abstract 317).
   Google Scholar
• KURODA Y, HARA K, TANABE K et al.: Effect of Cilostazol on long-term clinical outcome after Palmaz-Schatz stent implantation. Am. J Cardiol. (2000) 86(Suppl. 8A):120i (Abstract 315).
   PubMedGoogle Scholar
• PARKS, LEE CW, KIM H et al.: Effects of cilostazol on angiographic restenosis after coronary stent placement. Am. J. Cardiol. (2000) 86(5):499–503.
   PubMed Web of Science ®Google Scholar
• YANG Z, BIRKENHAUER P, JULMY F et al.: Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J. Control Release (1999) 60(2-3):269–277.
   PubMed Web of Science ®Google Scholar
• MISHRA-GORUR K, CASTELLOT JJ: Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. J Cell Physiol. (1999) 178(2):205–215.
   PubMed Web of Science ®Google Scholar
• KOHNO M, YOKOKAWA K, YASUNARI K et al.: Heparin inhibits human coronary artery smooth muscle cell migration. Metabolism (1998) 47(9):1065–1069.
   Google Scholar
• GOODWIN SC, YOON HC, WONG GC et al.: Percutaneous delivery of a heparin-impregnated collagen stent-graft in a porcine model of atherosclerotic disease. Invest. Radial. (2000) 35(7):420–425.
   PubMed Web of Science ®Google Scholar
• BAUMBACH A, OBERHOFF M, HERDEG C et al.: Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery. Basic Res. Cardiol. (2000) 95(3):173–178.
   PubMed Web of Science ®Google Scholar
• DEUTSCH E: The role of local low molecular weight heparin delivery in prevention of restenosis following coronary intervention. J. Invasive Cardiol. (1999) 11(Suppl. A):30A–32A.
   Google Scholar
• LABLANCHE JM, MCFADDEN EP, MENEVEAU N et al.: Effect of nadroparin, a low-molecular-weight heparin, on clinical andangiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
   Google Scholar
• MENEVEAU N, SCHIELE F, GROLLIER G et al.: Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study. Eur. Heart J. (2000) 21(21):1767–1775.
   PubMed Web of Science ®Google Scholar
• WILENSKY RL, TANGUAY JF, ITO S et al.: Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular deliveryon intimal hyperplasia. Am. Heart J. (2000)139(6): 1061–1070.
   PubMed Web of Science ®Google Scholar
• KIESZ RS, BUSZMAN P, MARTIN JL et al.: Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). Circulation (2001) 103(1):26–31.
   PubMed Web of Science ®Google Scholar
• CHENG Y, LIU P, CHEN H, ZENG F: Antiproliferative effects of trapidil in vascular smooth muscle cells are associated by inhibition of MAPK and P34(cdc2) activity. J. Cardiovasc. Pharmacol. (2000) 35(1):1–6.
   PubMed Web of Science ®Google Scholar
• BONISCH D, WEBER AA, WITTPOTH M, OSINSKI M, SCHROR K: Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A. Mal. Pharmacol. (1998) 54(2):241–248.
   PubMed Web of Science ®Google Scholar
• ZACHAROWSKI K, SCHNEIDMULLER D, IBE W et al.: Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model. Br. J. Pharmacol. (2000) 129(3):566–572.
   PubMed Web of Science ®Google Scholar
• DEGUCHI J, ABE J, MAKUUCHI M, TAKUWA Y: Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery. Lifi Sci. (1999) 65(26):2791–2799.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, INDEN M, SETSUDA M, KONISHI T, NAKANO T: Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. (1992) 123(6):1439–1444.
   Google Scholar
• MARESTA A, BALDUCELLI M, CANTINI L et al.: Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomised, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation (1994) 90(6):2710–2715.
   PubMed Web of Science ®Google Scholar
• GALASSI AR, TAMBURINO C, NICOSIA A et al.: A randomised comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz- Schatz stent implantation. Catheter Cardiovasc. Interv. (1999) 46(2):162–168.
   Google Scholar
• WESTERMANN AM, DUBBELMAN R, BAARS JP et al.: Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother. Pharmacol. (2000) 46(1):57–62.
   PubMed Web of Science ®Google Scholar
• ENGISCH R, SCHURMANN K, BIENERT H et al.: Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: potential drug for prevention of restenosis by local drug delivery. J. Vasc. Interv. Radial. (2000) 11(5):639–644.
   PubMed Web of Science ®Google Scholar
• HU Y, ZOU Y, DIETRICH H, WICK G, XU Q: Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation (1999) 100(8):861–868.
   PubMed Web of Science ®Google Scholar
• GRAY TJ, STRAUSS BH, HINEK A: Inhibitory mechanisms by which suramin may attenuate neointimal formation after balloon angioplasty. J Cardiovasc. Pharmacol. (1999) 33(6):960–971.
   Google Scholar
• ASADA Y, TSUNEYOSHI A, MARUTSUKA K, SUMIYOSHI A: Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovasc. Res. (1994) 28(8):1166–1169.
   PubMed Web of Science ®Google Scholar
• BOWDEN CJ, FIGG WD, DAWSON NA et al.: A Phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother. Pharmacol. (1996) 39(1-2):1–8.
   PubMed Web of Science ®Google Scholar
• ABDIU A, LARSSON SE, WASTESON A, WALZ TM: Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro. Cancer Lett. (1999) 146(2):189–194.
   PubMed Web of Science ®Google Scholar
• LUNDERGAN C, FOEGH ML, VARGAS R et al.: Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Atherosclerosis (1989) 80(1):49–55.
   PubMed Web of Science ®Google Scholar
• FOEGH ML, ASOTRA S, CONTE JV et al.: Early inhibition of myointimal proliferation by angiopeptin after balloon catheter injury in the rabbit. J. Vasc. Su. (1994) 19(6):1084–1091.
   PubMed Web of Science ®Google Scholar
• HOWELL MH, ADAMS MM, WOLFE MS, FOEGH ML, RAMWELL PW: Angiopeptin inhibition of myointimal hyperplasia after balloon angioplasty of large arteries in hypercholesterolaemic rabbits. Clin. Sci. (Colch.) (1993) 85(2):183–188.
   PubMed Web of Science ®Google Scholar
• SANTOIAN ED, SCHNEIDER JE, GRAVANIS MB et al.: Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation (1993) 88(1):11–14.
   PubMed Web of Science ®Google Scholar
• HONG MK, KENT KM, TIO FO et al.: Single-dose intramuscular administration of sustained-release angiopeptin reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Caron. Artery Dis. (1997) 8(2):101–104.
   PubMed Web of Science ®Google Scholar
• HONG MK, KENT KM, MEHRAN R et al.: Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Circulation (1997) 95(2):449–454.
   PubMed Web of Science ®Google Scholar
• DE SCHEERDER I, WILCZEK K, VAN DORPE J et al.: Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries. J. Invasive Cardiol. (1996) 8(5):215–222.
   PubMed Web of Science ®Google Scholar
• ERIKSEN UH, AMTORP O, BAGGER JP et al.: Randomised double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am. Heart J. (1995) 130(1):1–
   PubMed Web of Science ®Google Scholar
• EMANUELSSON H, BEATT KJ, BAGGER JP et al.: Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation (1995) 91(6):1689–1696.
   PubMed Web of Science ®Google Scholar
• VON ESSEN R, OSTERMAIER R, GRUBE E et al.: Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study. Verringerung der Restenoserate nach Angioplastie durch em n Somatostatin-analogon. Circulation (1997) 96(5):1482–1487.
   PubMed Web of Science ®Google Scholar
• FISHBEIN I, WALTENBERGER J, BANAT S et al.: Local delivery of platelet-derived growth factor receptor-specific tyrphostininhibits neointimal formation in rats. Arterioscler. Thromb. Vase. Biol. (2000) 20(3):667–676.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A:Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. (1999) 82(231–239).
   Google Scholar
• KUSAMA H, KIKUCHI S, TAZAWA S et al.: Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p2lwafl. Atherosclerosis (1999) 143(2):307–313.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI A, TANIGUCHI T, ISHIKAWA Y, YOKOYAMA M: Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(wafl /cipl/sdil) and p53. Circ. Res. (1999) 84(5):543–550.
   PubMed Web of Science ®Google Scholar
• UMEMURA K, KIKUCHI S, SUZUKI Y, NAKASHIMA M: Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart. Jpn j Pharmacol. (1998) 78(2):161–167.
   PubMedGoogle Scholar
• MIYAZAWA K, KIKUCHI S, FUKUYAMA J, HAMANO S, UJIIE A: Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis (1995) 118(2):213–221.
   PubMed Web of Science ®Google Scholar
• WATANABE S, MATSUDA A, SUZUKI Y et al.: Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors. Br. J. Pharmacol. (2000) 130(2):307–314.
   PubMed Web of Science ®Google Scholar
• FUKUYAMA J, MIYAZAWA K, HAMANO S, UJIIE A: Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can. J. Physiol Pharmacol. (1996) 74(1):80–84.
   PubMed Web of Science ®Google Scholar
• MIYAZAWA N, UMEMURA K, KONDO K, NAKASHIMA M: Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J. Cardiovasc. Pharmacol. (1997) 30(2):157–162.
   PubMed Web of Science ®Google Scholar
• OHLSTEIN EH, ROMANIC AM, CLARK LV et al.: Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery. Cardiovasc. Res. (2000) 47(4):759–768.
   PubMed Web of Science ®Google Scholar
• TAMAI H, KATOH O, SUZUKI S et al.: Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am. Heart J. (1999) 138(5 Pt 1):968–975.
   PubMed Web of Science ®Google Scholar
• M, SERRUYS PW, WILLERSON J, GRANETT JR et al: The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am. Heart J.(2000) 139(1 Pt 1):23–31.
   PubMed Web of Science ®Google Scholar
• NAKAMURA Y, NAKASHIMA S, FUJIMIYA H et al.: Effects of an antiallergic drug, pemirolast potassium on tyrosinephosphorylation and map kinase activation in antigen-stimulated rat basophilicleukemia (RBL-2H3) cells. Arerugi (1995) 44(1):34–44.
   PubMedGoogle Scholar
• FUJIMIYA H, NAKASHIMA S, KUMADA T et al.: An antiallergic drug, pemirolast potassium, inhibits inositol 1,4,5-trisphosphate production and Ca2* mobilization in antigen-stimulated ratbasophilic leukemia (RBL-2H3) cells. Arerugi (1994) 43(2 Pt 1):142–151.
   PubMedGoogle Scholar
• YOSHINUMA M: Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies. J. Cardia (1999) 33(2):81–88.
   Google Scholar
• OHSAWA H, NOIKE H, KANAI M et al.: Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. (1998) 136(6):1081–1087.
   PubMed Web of Science ®Google Scholar
• KHANNA AK: Mechanism of the combination immunosuppressive effects of rapamycin with eithercyclosporine or tacrolimus. Transplantation (2000) 27;70(4):690–694.
   PubMed Web of Science ®Google Scholar
• CHOI JH, ADAMES NR, CHAN TF et al.: XF.TOR signaling regulates microtubule structure and function. Curr. Biol. (2000) 10(14):861–864.
   PubMed Web of Science ®Google Scholar
• POON M, MARX SO, GALLO R et al.: Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. (1996) 96(10):2277–2283.
   Google Scholar
• BURKE SE, LUBBERS NL, CHEN YNXT et al.: Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. j Cardiovasc. Pharmacol. (1999) 33(6):829–835.
   PubMed Web of Science ®Google Scholar
• GALLO R, PADUREAN A, JAYARAMAN T et al.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 99(16):2164–2170.
   PubMed Web of Science ®Google Scholar
• SOUSA JE, COSTA MA, ABIZAID A et al.: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries a quantitative coronary angiography and three-dimensional intravascular ultrasound study.Circulation (2001) 103(2):192–195.
   PubMed Web of Science ®Google Scholar
• AXEL DI, KUNERT W, GOGGELMANN C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation (1997) 96(2):636–645.
   PubMed Web of Science ®Google Scholar
• SOLLOTT SJ, CHENG L, PAULY R ROWINSKY EK et al.: Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. j Clin. Invest. (1995) 95(4):1869–1876.
   PubMed Web of Science ®Google Scholar
• HERDEG C, OBERHOFF M, SIEGEL-AXEL DI et al.: Paclitaxel: a chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo. Z. Kardiol (2000) 89(5):390–397.
   Google Scholar
• DRACHMAN DE, EDELMAN ER,SEIFERT P et al.: Neointimal thickening after stent delivery of paclitaxel:Change in composition and arrest of growth over six months. J. Am. Coll. Cardiol (2000) 36(7):2325–2332.
   PubMed Web of Science ®Google Scholar
• HELDMAN AW, CHENG L, HELLER P et al.: Paclitaxel applied directly to stents inhibits neointimal growth without thrombotic complications in a porcine coronary artery model of restenosis. Circulation (1997) 96:636–645.
   PubMedGoogle Scholar
• LE TOURNEAU T, VAN BELLE E, CORSEAUX D et al.: Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodelling. j Am. Coll. Cardiol (1999) 33(3):876–882.
   PubMed Web of Science ®Google Scholar
• BUERGLER JM, TIO FO, SCHULZ DG et al.: Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. Caron. Artery Dis. (2000) 11(4):351–357.
   PubMed Web of Science ®Google Scholar
• LABLANCHE JM, GROLLIER G, LUSSON JR et al.: Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Circulation (1997) 95(1):83–89.
   PubMed Web of Science ®Google Scholar
• PINES M, NAGLER A: Halofuginone: a novel antifibrotic therapy. Gen. PharmacoL (1998) 30(4):445–450.
   PubMedGoogle Scholar
• NAGLER A, MIAO HQ, AINGORN H et al.: Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vase. Biol. (1997) 17(1):194–202.
   PubMed Web of Science ®Google Scholar
• LIU K, SEKINE S, GOTO Y et al.: Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro. Heart Vessels (1998) 13(1):18–23.
   PubMed Web of Science ®Google Scholar
• KEELAN PC, BAYES-GENIS A, KANG JH et al.: Halofuginone an inhibitor of collagen synthesis, reduces neointimal hyperplasia in a porcine coronary stent model. Circulation (2000) 102 (18):I1732. Abstract 3541.
   Google Scholar
• HENDRICKSON RJ, CAHILL PA, MCKILLOP IH, SITZMANN JV, REDMOND EM: Ethanol inhibits mitogen activated protein kinase activity and growth of vascular smooth muscle cells in vitro. Eur. J. Pharmacol (1998) 362(2-3):251–259.
   PubMed Web of Science ®Google Scholar
• MERRITT R, GURUGE BL, MILLER DD, CHAITMAN BR, BORA PS: Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model. J. Cardiovasc. Pharmacol (1997) 30(1):19–25.
   PubMed Web of Science ®Google Scholar
• LIU MW, ANDERSON PG, LUO JF, ROUBIN GS: Local delivery of ethanol inhibits intimal hyperplasia in pig coronary arteries after balloon injury. Circulation (1997) 96(7):2295–2301.
   PubMed Web of Science ®Google Scholar
• LIU MW, LIN SJ, CHEN YL: Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury. Atherosclerosis (1996) 127(2):221–227.
   PubMed Web of Science ®Google Scholar
• CURRAN MJ, FRY TL, SCHREIBER CL et al.: Initial human experience with intramural ethyl alcohol treatment of in-stent restenosis: The Beaumont Alcoholc Restenosis Study (BARS). Am. J. Cardiol (2000) 86(Suppl. 8A):25i. Abstract 59.
   PubMedGoogle Scholar
• LIU MW, ALRED D, MAEHARA A et al.: Safety study of coronary intramural ethyl alcohol delivery in reducing intimal hyperplasia after successful coronary stenting. Am. J. Cardiol. (2000) 86(Suppl. 8A):25i. Abstract 60.
   Google Scholar
• RIESSEN R, AXEL DI, FENCHEL M et al.: Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res. CardioL (1999) 94(5):322–332.
   PubMed Web of Science ®Google Scholar
• AXEL DI, RIESSEN R, RUNGE H, VIEBAHN R, KARSCH KR: Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. j Cardiovasc. Pharrnacol. (2000) 35(4):619–629.
   PubMed Web of Science ®Google Scholar
• CORSINI A, BERNINI F, QUARATO P et al.: Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology (1996) 87(6):458–468.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, BERNINI F, FERRI N et al.: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis (1998) 137(Suppl.):S 101–5109.
   PubMed Web of Science ®Google Scholar
• KNAPP AC, HUANG J, STARLING G, KIENER PA: Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to fas-ligand and cytokine-induced cell death. Atherosclerosis. (2000) 152(1) 217–227.
   PubMed Web of Science ®Google Scholar
• KOMUKAI M, WAJIMA YS, TASHIRO J et al.: Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Scand. Clin. Lab. Invest. (1999) 59(3):159–166.
   PubMed Web of Science ®Google Scholar
• SAHNI R, MANIET AR, VOCI G, BANKA: Prevention of restenosis by lovastatin after successful coronary angioplasty. Am. Heart J. (1991) 12: 1600–1618.
   Google Scholar
• WEINTRAUB WS, BOCCUZZI SJ, KLEIN JL et al.: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N. Engl j Med. (1994) 331(20):1331–1337.
   PubMed Web of Science ®Google Scholar
• O'KEEFE JH JR, STONE GW, MCCALLISTER BD, JR. et al.: Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol (1996) 77(8):649–652.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, MCFADDEN EP, FRUCHART JC et al.: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J. Am. Coll. Cardiol (1997) 30(4):863–869.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, FOLEY DP, JACKSON G et al.: A randomised placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. (1999) 20(1):58–69.
   PubMed Web of Science ®Google Scholar
• WALTER DH, SCHACHINGER V, ELSNER M et al.: Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol (2000) 85(8):962–968.
   PubMed Web of Science ®Google Scholar
• THE 4S INVESTIGATORS: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383–1389.
   Google Scholar
• ARAKI S, KAWAHARA Y, KARIYA K et al.: Stimulation of platelet-derived growth factor-induced DNA synthesis by angiotensin II in rabbit vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1990) 168:350–357.
   PubMed Web of Science ®Google Scholar
• NATARAJAN R, GONZALES N, LANTING L, NADLER J: Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension (1994) 23\(Suppl. 1):I-142-I–147.
   Google Scholar
• CAMPBELL-BOSWELL M, ROBERTSON AL JR: Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp. Mal. Pathol. (1981) 35:265–276.
   PubMed Web of Science ®Google Scholar
• DAEMEN MJAP, LOMBARDI DM, BOSMAN FT, SCHWARTZ SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. (1991) 68:450–456.
   PubMed Web of Science ®Google Scholar
• GEISTERFERAAT, PEACH MJ, OWENS GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. (1988) 62:749–756.
   PubMed Web of Science ®Google Scholar
• WILSON DP, SAWARD L, ZAHRADKA P, CHEUNG PK: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc. Res. (1999) 42(3):761–772.
   PubMed Web of Science ®Google Scholar
• HUBER KC, SCHWARTZ RS, EDWARDS WD et al.: Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am. Heart J. (1993) 125(3):695–701.
   PubMed Web of Science ®Google Scholar
• CLOZEL JP, HESS P, MICHAEL C, SCHIETINGER K, BAUMGARTNER HR: Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension (1991) 18\(Suppl. 4):I155–59.
   Google Scholar
• KALINOWSKI M, TEPE G, SCHIEBER A et al.: Local administration of ramiprilat is less effective than oral ramipril in preventing restenosis after balloon angioplasty in an animal model. J. Vase. Interv. Radial. (1999) 10(10):1397–1404.
   PubMed Web of Science ®Google Scholar
• LI J, WANCHUN C: Benazepril on tissue angiotensin-converting enzyme and cellular proliferation in restenosis after experimental angioplasty. J. Cardiovasc. Pharmacol. (1997) 30(6):790–797.
   PubMed Web of Science ®Google Scholar
• POWELL JS, MULLER RK, BAUMGARTNER HR: Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J. Am. Coll. Cordial. (1991) 17(6 Suppl. B):137B–142B.
   Google Scholar
• CHURCHILL DA, SIEGEL CO, MINOR ST, WEST MS, RAIZNER AE: Enalapril in the prevention of restenosis following intracoronary intervention in a swine model. Caron. Artery Dis. (1993) 4(5):461–467.
   PubMed Web of Science ®Google Scholar
• BROZOVICH FV, MORGANROTH J, GOTTLIEB NB, GOTTLIEB RS: Effect of angiotensin converting enzyme inhibition on the incidence of restenosis after percutaneous transluminal coronary angioplasty. Cathet. Cardiovasc. Diagn. (1991) 23(4):263–267.
   PubMedGoogle Scholar
• KAUL U, CHANDRA S, BAHL VK, SHARMA S, WASIR HS: Enalapril for prevention of restenosis after coronary angioplasty. Indian Heart J. (1993) 45(6):469–473.
   PubMedGoogle Scholar
• MERCATOR STUDY GROUP: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomised, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis. Circulation (1992) 86(1):100–110.
   PubMed Web of Science ®Google Scholar
• FAXON DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group./ Am. Coll. Cordial. (1995) 25(2):362–369.
   PubMed Web of Science ®Google Scholar
• PETERS S, GOTTING B, TRUMMEL M, RUST H, BRATTSTROM A: Valsartan for prevention of restenosis after stenting of type b2/c lesions: the val-prest trial./ Invasive Cordial. (2001) 13(2):93–97.
   PubMed Web of Science ®Google Scholar
• KONDO J, SONE T, TSUBOI H et al.: Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am. J. Cordial. (2001) 87(4):443–445. Abstract 6.
   PubMed Web of Science ®Google Scholar
• MEURICE T, BAUTERS C, HERMANT X et al.: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet (2001) 357(9265):1321–1324.
   PubMed Web of Science ®Google Scholar
• VOISARD R, SEITZER U, BAUR R et al.: Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int. J. Cordial. (1994) 43(3):257–267.
   PubMed Web of Science ®Google Scholar
• DAI-DO D, ESPINOSA E, LIU G et al.: 17 beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. Cardiovasc. Res. (1996) 32(5):980–985.
   PubMed Web of Science ®Google Scholar
• STRECKER EP, GABELMANN A, BOOS I et al.: Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc. Intervent Radial. (1998) 21(6):487–496.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, FURST JG, ELLIS SG, TUCH RJ, TOPOL EJ: Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J. Am. Goa Cordial. (1997) 29(4):808–816.
   PubMed Web of Science ®Google Scholar
• MULLER DW, GOLOMB G, GORDON D, LEVY RJ: Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Caron. Artery Dis. (1994) 5(5):435–442.
   PubMed Web of Science ®Google Scholar
• STONE GW, RUTHERFORD BD, MCCONAHAY DR et al.: A randomised trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet.Cardiavasc. Diagn. (1989) 18(4):227–231.
   PubMedGoogle Scholar
• PEPINE CJ, HIRSHFELD JW MACDONALD RG et al.: A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation (1990) 81(6):1753–1761.
   Google Scholar
• LEE CW, CHAE JK, LIM HY et al.: Prospective randomised trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am. Heart J. (1999) 138(1 Pt 1):60–63.
   PubMed Web of Science ®Google Scholar
• REIMERS B, MOUSSA I, AKIYAMA T et al.: Persistent high restenosis after local intrawall delivery of long-acting steroids before coronary stent implantation. J. Invasive CardioL (1998) 10(6):323–331.
   PubMed Web of Science ®Google Scholar
• REIS ED, ROQUE M, DANSKY H et al: Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc. Nail. Acad. Sci. USA (2000) 97(23):12764–12769.
   PubMed Web of Science ®Google Scholar
• AZEVEDO LC, PEDRO MA, SOUZA LC et al.: Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc. Res. (2000) 47(3):436–445.
   PubMed Web of Science ®Google Scholar
• TANAKA K, HAYASHI K, SHINGU T et al.: Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc. Drugs Ther. (1998) 12(1):19–28.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI K, AIKAWA M, TANI T et al: Effect of probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: possible role of PDGF. Cardiovasc. Drugs Ther. (1998) 12 (3):251–260.
   PubMed Web of Science ®Google Scholar
• FERNS GA, FORSTER L, STEWART-LEE A et al: Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc. Natl. Acad. Sci. USA (1992) 89(23):11312–11316.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER JE, BERK BC, GRAVANIS MB et al.: Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation (1993) 88(2):628–637.
   PubMed Web of Science ®Google Scholar
• YOKOI H, DAIDA H, KUWABARA Y et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J. Am. Coil. CardioL (1997) 30(0855–862.
   PubMed Web of Science ®Google Scholar
• WATANABE K, SEKIYA M, IKEDA S, MIYAGAWA M, HASHIDA K: Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. (1996) 132(1 Pt 1):23–29.
   PubMed Web of Science ®Google Scholar
• SETSUDA M, INDEN M, HIRAOKA N et al: Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin. Ther. (1993) 15(2):374–382.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, COTE G, LESPERANCE J et al: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N EngL f. Med. (1997) 337(6):365–372.
   PubMed Web of Science ®Google Scholar
• DAIDA H, KUWABARA Y, YOKOI H et al.: Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am. J. CardioL (2000) 86(5):550–552. Abstract 9.
   PubMed Web of Science ®Google Scholar
• LEE YJ, DAIDA H, YOKOI H et al: Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. (1996) 37(3):327–332.
   PubMedGoogle Scholar
• COTE G, TARDIF JC, LESPERANCE J et al.: Effects of probucol on vascular remodelling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation (1999) 99(1):30–35.
   PubMed Web of Science ®Google Scholar
• SEKIYA M, FUNADA J, WATANABE K, MIYAGAWA M, AKUTSU H: Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am. J. CardioL (1998) 82(2):144–147.
   PubMed Web of Science ®Google Scholar
• LAU A, LEICHTWEIS S, CHAUFOUR X, WITTING PK, CELERMAJER DS, STOCKER R: Probucol promotes re-endotheliazation after balloon injury. Circulation (2000) 102(Suppl. II):317. Abstract 1551.
   Google Scholar
• LAW RE, MEEHAN WP, XI XP et al: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. Clin. Invest. (1996) 98(8):1897–1905.
   Google Scholar
• GOETZE S, XI XP, KAWANO H et al: PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. PharmacoL (1999) 33(5):798–806.
   PubMed Web of Science ®Google Scholar
• SHINOHARA E, KIHARA S, OUCHI N et al.: Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis. (1998) 136(2):275–279.
   PubMed Web of Science ®Google Scholar
• TAKAGI T, AKASAKA T, YAMAMURO A et al.: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J. Am. Coil. CardioL (2000).
   Google Scholar
• BENDECK MP, ZEMPO N, CLOWES AW, GALARDY RE, REIDY MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. (1994) 75(3):539–545.
   PubMed Web of Science ®Google Scholar
• STRAUSS BH, ROBINSON R, BATCHELOR WB et al.: In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ. Res. (1996) 79(3):541–550.
   PubMed Web of Science ®Google Scholar
• SIEREVOGEL MJ, PASTERKAMP G, VELEMA E et al: Oral matrix metalloproteinase inhibition and arterial remodelling after balloon dilation: an intravascular ultrasound study in the pig. Circulation (2001) 103(2):302–307.
   PubMed Web of Science ®Google Scholar
• LI CW, CANTOR WJ, ROBINSON R et al: Matrix metalloproteinase inhibitor GM6001 selectively reduce intimal hyperplasia and intimal collagen content in stented but not balloon treated arteries. j Am. Coil. CardioL (2000) 35(Suppl. A):28A.
   Google Scholar
• LOVDAHL C, THYBERG J, HULTGARDH-NILSSON A: The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ ERK2 and phenotypic modification of arterial smooth muscle cells in vitro. J. Vasc. Res. (2000) 37(5):345–354.
   PubMed Web of Science ®Google Scholar
• RIESSEN R, WIGHT TN, PASTORE C, HENLEY C, ISNER JM: Distribution of hyaluronan during extracellular matrix remodelling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation (1996) 93(6):1141–1147.
   PubMed Web of Science ®Google Scholar
• TRAVIS JA, HUGHES MG, WONG JM, WAGNER WD, GEARY RL: Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: role of CD44 and implications for constrictive remodelling. Circ. Res. (2001) 88(1):77–83.
   PubMed Web of Science ®Google Scholar
• CHAJARA A, LEVESQUE H: Role of hyaluronic acid in the arterial response to angioplasty. PathoL BioL (Paris). (1998) 46(7):561–570.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation, and signaling in cell adhesion. CelL (1992) 69(1):11–25.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: Integrins. J. Clin. Invest. (1991) 87(1):1–5.
   PubMed Web of Science ®Google Scholar
• CHOI ET, ENGEL L, CALLOWAD et al: Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. Vasc. Su. (1994) 19(1):125–134.
   PubMed Web of Science ®Google Scholar
• SLEPIAN MJ, MASSIA SP, DEHDASHTI B, FRITZ A, WHITESELL L: Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation (1998) 97(18):1818–1827.
   PubMed Web of Science ®Google Scholar
• SHATTIL SJ: Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb. Haemost. (1995) 74(1):149–155.
   PubMed Web of Science ®Google Scholar
• WEERASINGHE D, MCHUGH KP, ROSS FP et al.: A role for the alphavbeta3 integrin in the transmigration of monocytes. J. Cell Biol. (1998) 142(2):595–607.
   PubMed Web of Science ®Google Scholar
• STOUFFER GA, HU Z, SAJID M et al.: Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation (1998) 97(9):907–915.
   PubMed Web of Science ®Google Scholar
• BENDECK MP, IRVIN C, REIDY M et al.: Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb. Vase. Biol. (2000) 20(6):1467–1472.
   PubMed Web of Science ®Google Scholar
• WERB Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell (1997) 91(4):439–442.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, SANDERS LC et al.: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 85(5):683–693.
   PubMed Web of Science ®Google Scholar
• PICKERING JG, CHOW LH, LI S et al.: alpha5betal integrin expression and luminal edge fibronectin matrix assembly _ k y smooth muscle cells after arterial injury. Am. J. PathoL (2000) 156(2):453–465.
   PubMed Web of Science ®Google Scholar
• VAN DER ZEE R, MUROHARA T, PASSERI J et al.: Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes. Commun. (1998) 6(5):371–379.
   PubMedGoogle Scholar
• COLEMAN KR, BRADEN GA, WILLINGHAM MC, SANE DC: Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ. Res. (1999) 84(11):1268–1276.
   PubMed Web of Science ®Google Scholar
• BISHOP GG, MCPHERSON JA, SANDERS JM et al.: Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation (2001) 103(14):1906–1911.
   PubMed Web of Science ®Google Scholar
• ROGERS C, EDELMAN ER, SIMON DI: A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc. Natl. Acad. Sci. USA (1998) 95(17):10134–10139.
   PubMed Web of Science ®Google Scholar
• ZHU NL, WU L, LIU PX et al.: Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation (1997) 96(2):628–635.
   PubMed Web of Science ®Google Scholar
• KANEDA Y, MORISHITA R, DZAU VJ: Prevention of restenosis by gene therapy. Ann. NY Acad. Sci. (1997) 811:299–308.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, KANEDA Y, OGIHARA T, DZAU VJ: Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene (1994) 149(1):13–19.
   PubMed Web of Science ®Google Scholar
• PICKERING JG, ISNER JM, FORD CM et al.: Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty. Circulation (1996) 93(4):772–780.
   PubMed Web of Science ®Google Scholar
• MANN MJ, WHITTEMORE AD, DONALDSON MC et al.: Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet (1999) 354(9189):1493–1498.
   PubMed Web of Science ®Google Scholar
• SHEARS LL 2ND, KIBBE MR, MURDOCK AD et al.: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J. Am. Coll. Surg. (1998) 187(3):295–306.
   PubMed Web of Science ®Google Scholar
• JIN G, CHIEH-HSI WU J et al.: Effects of active and negative mutants of ras on rat arterial neointima formation. J Surg Res. (2000) 94(2):124–132.
   PubMed Web of Science ®Google Scholar
• LAMPHERE L, TSUI L, WICK S et al.: Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy. J MoL Med. (2000) 78(8):451–459.
   PubMed Web of Science ®Google Scholar
• VARENNE O, SINNAEVE P: Gene therapy for coronary restenosis: a promising strategy for the new millennium? Curr. Interv. CardioL Rep. (2000) 2(4):309–315.
   PubMedGoogle Scholar